FDA panel votes against OTC use of OAB agent

Article

An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.